Meet with… The National Institute on Drug Abuse

Oct 27 2016

NIDA: Advancing Science on Causes and Consequences of Drug Use and Addiction

On a mission to improve public health? Let The National Institute on Drug Abuse (NIDA) help you get there. NIDA is the leading federal agency providing funding to support and advance the science on the causes and consequences of drug use (including nicotine) and addiction and to apply that knowledge to improve individual and public health. NIDA supports the activities in neurobiological, behavioral, and social fields and, through its Small Business Innovation Research program (SBIR), assists US-based small business to develop new drug discovery and development-enabling technologies, useful research tools for conducting basic research, medical devices and mobile health applications.

NIDA's Scientific Program Manager Victor Prikhodko and Director of the Office of Translational Initiatives and Program Innovations Elena Koustova will be in attendance on October 27th to discuss NIDA SBIR funding opportunities, explain the application process, and present some best practices for strong applications. In 2015, NIDA awarded over $980 million in total funds, with more than $20 million specifically dedicated to awards to small businesses.

NIDA SBIR Phase I grants are typically $150k-$350k and the application requires a short 6-page research strategy document. Phase II awards can range from $1 million to $2.5 million.

Following the presentation, don't miss the opportunity to introduce yourself to Victor and Elena during the networking lunch. And, finally, for those companies who applied online and were approved, one-on-one meetings with NIDA will provide an intimate forum to discuss your company.

11:30 AM | Registration Opens, Lunch and Networking
12:00 PM | Presentation and Q&A
12:45 PM | Networking
1:00 PM | Program Close
1:00-5:00 PM | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and been approved. The application period ended on September 27th.

NIDA Participating Representatives:
Elena Koustova | Director of the Office of Translational Initiatives and Program Innovations, NIDA read bio»
Victor Prikhodko | Scientific Program Manager, NIDA read bio»

Presentation & Lunch
$25 | General Public
$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on October 26th (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ended on September 27th. Your application will be reviewed and you will be notified of acceptance by email on October 6th. Acceptance of one-on-one meetings is not guaranteed as all applications must be approved.

About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, NCI, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCATS, NINDS, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.

NIDA Representatives' Biographies:
Elena Koustova | Director of the Office of Translational Initiatives and Program Innovations, NIDA
Elena Koustova is currently the Director of the Office of Translational Initiatives and Program Innovations at the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, DHHS. She directs NIDA's Small Business Innovation Research (SBIR/STTR) Program, and engages in trans-NIH translational activities, including NIH Blueprint Neurotherapeutics Network. She also serves as NIDA Challenge Manager, and is responsible for managing and coordinating the implementation of a prize authority at NIDA. In addition, Elena is involved in NIH Initiative on Rigor and Reproducibility and is an NIH Representative and the member of the managing team of the ECNP Preclinical Data Network (PDN) comprised of the representatives of major pharmaceutical companies and academia specifically focused on addressing the issues of rigor, robustness and reproducibility in preclinical research. Elena Koustova received her Ph.D. in Neuroscience from Moscow State University and subsequently completed a postdoctoral fellowship at the National Institutes of Health. Before joining NIDA in 2008, she served as Associate Professor at the F. Edward Hébert School of Medicine, Bethesda, MD and R&D Director at DOV Pharmaceutical, Inc., Somerset, NJ.

Victor Prikhodko | Scientific Program Manager, NIDA
Victor Prikhodko is a Scientific Program Manager within the Office of Translational Initiatives and Program Innovations (OTIPI) which supports the National Institute on Drug Abuse (NIDA) and administers a $30M/Y Small Business Fund (SBIR/STTR Programs). Through the fund, NIDA has invested in small businesses developing substance abuse products and services ranging from therapeutics, research tools, diagnostics, medical devices, and health IT to education. Victor previously held positions at ABL, RHT Consulting and Aeras Global. At ABL, a leading contract research and manufacturing organization, Victor oversaw a $100M preclinical development support contract with the National Institute of Allergies and Infectious Disease (NIAID) which focused on evaluating and moving the most promising biologics through product development and into Phase I clinical trials. At Aeras, Victor managed the company's R&D Adenovirus portfolio. This included developing internal lead vaccine candidates and co-developing next generation vaccines with industry partners including Okairos (Acquired by GSK), Crucell (Acquired by J&J) and Oxford University. His role also included creating and implementing a business development and branding strategy for the company's Contract Manufacturing Operations while contributing and participating in various committees and project groups which determine which vaccine candidates move from pre-clinical development to human clinical studies. Victor graduated from the University of Maryland with a degree in Microbiology and an MBA in Interdisciplinary Studies from Johns Hopkins Carey Business School. In his free time, Victor enjoys being a father, a husband, working on a never ending honey to do list, and training his two dogs.
Connect with Victor: Connect on LinkedIn

MassBio HQ
300 Technology Square, 8th Floor
Collaboration Room
Cambridge, MA